<DOC>
	<DOCNO>NCT00144196</DOCNO>
	<brief_summary>To show treatment tiotropium inhalation capsule ( 18 μg q.d . ) via HandiHaler® improve lung function patient mild COPD accord Swedish guideline .</brief_summary>
	<brief_title>12 Week Efficacy Tiotropium Versus Placebo Patients With Mild COPD According Swedish Guidelines ( SPIRIMILD )</brief_title>
	<detailed_description>Following initial screen screen visit ( Visit 1 ) , patient enter 2 week run-in period . Patients allow take salbutamol ( Ventoline , Diskus , 0.2 mg ) prn rescue medication record daily use Patient 's Diary . Patients meet inclusion none exclusion criterion check Visit 2 randomise thereafter randomise treatment period study receive either tiotropium ( Spiriva ) placebo blind fashion . On Day 0 ( Visit 2 ) , first administration blind study medication ( tiotropium ( Spiriva ) match placebo ) perform study site , pre-dose pulmonary function test ( PFT ) carry . First administration blind study medication monitor investigator . Post dose PFTs perform 30 min , 1 2 hour . On Days 1 83 except Day 14 , blind study medication self-administered patient home . The patient inhale one capsule ( tiotropium ) ( Spiriva ) match placebo ) use HandiHaler device daily morning . The morning dose blind study medication take approximately time morning 7:00 a.m. 10:00 a.m. At visit 3 4 PFTs perform predose post dose 30 minute , 1 2 hour Study Hypothesis : The rationale study show treatment tiotropium ( Spiriva ) 18 ? g inhalation capsule via HandiHaler daily improves FEV1 compare placebo patient mild COPD accord Swedish guideline , i.e. , post-bronchodilator FEV1 &lt; 60 % predict normal FEV1 &lt; 70 % FVC . Comparison ( ) : One group treat inhalation powder capsule tiotropium ( Spiriva ) , 18 microgram daily . The group treat match placebo . Randomisation 1:1</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . Patients sign write informed consent consistent ICH GCP guideline local legislation prior participation trial . 2 . Patients diagnosis COPD . COPD define disease state characterise presence airflow obstruction often due chronic bronchitis emphysema ; airflow obstruction generally progressive , may accompany airway hyperreactivity , may partially reversible . 3 . Patients 40 year age old without restriction sex . 4 . Patients currently smoke exsmokers cigarette smoke history &gt; 10 packyears . 5 . Patients relatively stable airway obstruction ( least 4 week free COPD exacerbation ) post bronchodilator FEV1 ? 60 % predict normal , post bronchodilation FEV1 &lt; 70 % FVC , MRC symptom score minimum 2 Visit 1 1 . Patients history asthma , allergic rhinitis , atopy , total ( absolute ) blood eosinophil count ? 600 per mm3 ( = 0.6 * 109/L ) first determination Visit 1 2 . Patients know moderate severe renal insufficiency . 3 . Patients recent history ( i.e. , 6 month less prior Visit 1 ) myocardial infarction . 4 . Patients unstable life threaten cardiac arrhythmia , include patient newly diagnose , clinically relevant arrhythmia electrocardiogram ( ECG ) perform Visit 1 well patient cardiac arrhythmia require intervention ( i.e. , hospitalisation , cardioversion , pacemaker placement , automatic implantable cardiac defibrillator ( AICD ) placement ) change drug therapy last year prior Visit 1 . 5 . Patients regularly use oxygen therapy . 6 . Patients know active tuberculosis . 7 . Patients history cancer within last 5 year . Patients treat basal cell carcinoma allow . 8 . Patients history life threaten pulmonary obstruction history cystic fibrosis clinically evident bronchiectasis . 9 . Patients undergone thoracotomy pulmonary resection . 10 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program 6 week prior screen visit ( Visit 1 ) . 11 . Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system . 12 . Patients know symptomatic hyperplasia bladder neck obstruction . Patients treat prostatic hyperplasia report minimal symptom may include continue medication . 13 . Patients know narrowangle glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>